ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
16 Noviembre 2023 - 8:00AM
Business Wire
ImmunityBio, Inc. (NASDAQ: IBRX), a
clinical-stage immunotherapy company, announced today that the
company will be participating in the 35th Annual Piper Sandler
Healthcare Conference, which is taking place in New York City,
November 28-30, 2023.
Details of the presentation can be found below.
Piper Sandler Healthcare
Conference
Date
Thursday, November 30, 2023
Time:
10:30 am EST
Format:
Fireside chat with Director and Senior
Research Analyst Joseph Catanzaro, Ph.D.
Webcast Link:
https://event.webcasts.com/starthere.jsp?ei=1644522&tp_key=54f83a05b0
A replay of the presentation will be available by visiting the
"Events” section of the ImmunityBio website and will be archived
for 90 days.
About ImmunityBio
ImmunityBio is a vertically-integrated, clinical-stage
biotechnology company developing next-generation therapies and
vaccines that bolster the natural immune system to defeat cancers
and infectious diseases. The company’s range of immunotherapy and
cell therapy platforms, alone and together, act to drive and
sustain an immune response with the goal of creating durable and
safe protection against disease. We are applying our science and
platforms to treating cancers, including the development of
potential cancer vaccines, as well as developing immunotherapies
and cell therapies that we believe sharply reduce or eliminate the
need for standard high-dose chemotherapy. These platforms and their
associated product candidates are designed to be more effective,
accessible, and easily administered than current standards of care
in oncology and infectious diseases.
For more information, please visit: www.immunitybio.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, such as statements regarding conference participation and
timing, the development of therapeutics for cancers and infectious
diseases, ImmunityBio’s product candidates as compared to existing
treatment options, and the regulatory review process, among others.
Statements in this press release that are not statements of
historical fact are considered forward-looking statements, which
are usually identified by the use of words such as “anticipates,”
“believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,”
“expects,” “intends,” “may,” “plans,” “potential,” “predicts,”
“indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and
variations of such words or similar expressions. Statements of past
performance, efforts, or results of our preclinical and clinical
trials, about which inferences or assumptions may be made, can also
be forward-looking statements and are not indicative of future
performance or results. Forward-looking statements are neither
forecasts, promises nor guarantees, and are based on the current
beliefs of ImmunityBio’s management as well as assumptions made by
and information currently available to ImmunityBio. Such
information may be limited or incomplete, and ImmunityBio’s
statements should not be read to indicate that it has conducted a
thorough inquiry into, or review of, all potentially available
relevant information. Such statements reflect the current views of
ImmunityBio with respect to future events and are subject to known
and unknown risks, including business, regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about ImmunityBio, including, without limitation, (i) the risks and
uncertainties associated with the regulatory review process, (ii)
the ability of ImmunityBio and its third party contract
manufacturing organizations to adequately address the issues raised
in the FDA’s complete response letter, (iii) the ability of
ImmunityBio to continue its planned preclinical and clinical
development of its development programs, and the timing and success
of any such continued preclinical and clinical development and
planned regulatory submissions, (iv) ImmunityBio’s ability to
retain and hire key personnel, (v) ImmunityBio’s ability to obtain
additional financing to fund its operations and complete the
development and commercialization of its various product
candidates, (vi) ImmunityBio’s ability to successfully
commercialize its product candidates and uncertainties around
regulatory reviews and approvals, (vii) ImmunityBio’s ability to
scale its manufacturing and commercial supply operations for its
product candidates and future approved products, and (viii)
ImmunityBio’s ability to obtain, maintain, protect and enforce
patent protection and other proprietary rights for its product
candidates and technologies. More details about these and other
risks that may impact ImmunityBio’s business are described under
the heading “Risk Factors” in the Company’s Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on March 1,
2023 and the Company’s Form 10-Q filed with the SEC on November 9,
2023, and in subsequent filings made by ImmunityBio with the SEC,
which are available on the SEC’s website at www.sec.gov.
ImmunityBio cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date hereof.
ImmunityBio does not undertake any duty to update any
forward-looking statement or other information in this press
release, except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231116785447/en/
Investors Hemanth Ramaprakash, PhD, MBA
ImmunityBio, Inc. +1 858-746-9289
Hemanth.Ramaprakash@ImmunityBio.com
Media Greg Tenor Salutem +1 717-919-6794
Gregory.Tenor@Salutem.com
ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024